Member of Commission IX DPR RI, Netty Prasetiyani Aher, has expressed\nsupport for the government\u2019s plan to include certain herbal medicines in\nthe BPJS Kesehatan financing scheme. She stated that the policy could\nstrategically strengthen national health sector independence and boost\nthe development of the domestic herbal industry based on scientific\nresearch.<\/p>\n
Netty noted Indonesia\u2019s significant potential for developing herbal\nmedicines due to its biodiversity and long-standing traditional herbal\npractices.<\/p>\n
\u201cIndonesia possesses abundant biodiversity and traditional herbal\nmedicine practices. However, to be included in the national healthcare\nsystem and BPJS financing, scientific standards, safety, and efficacy\nmust be the top priority,\u201d Netty said in a statement on Saturday (30\nMay).<\/p>\n
She cautioned that not all herbal or jamu products would\nautomatically receive BPJS Kesehatan coverage, stressing only those\nmeeting scientific standards should be part of national healthcare\nservices.<\/p>\n
Netty supported the stance of the Food and Drug Supervisory Agency\n(BPOM), which prioritises fitofarmaka products that have undergone\nclinical trials and have strong scientific evidence for inclusion in the\nNational Health Insurance (JKN) system.<\/p>\n
\u201cLet\u2019s not let the public misunderstand that all jamu will be covered\nby BPJS. The focus should be on products thoroughly tested\nscientifically, safe, and beneficial for patients,\u201d she said.<\/p>\n
The Prosperous Justice Party (PKS) politician added that the policy\ncould drive the national herbal medicine industry, which has faced\nchallenges, particularly in research funding and product\ndevelopment.<\/p>\n
\u201cDeveloping fitofarmaka requires substantial investment, long\ntimelines, and complex research processes. Therefore, the state must\ncreate an ecosystem that provides certainty for the industry without\ncompromising patient safety,\u201d she explained.<\/p>\n
On another note, Netty urged stricter oversight of herbal product\ndistribution, highlighting the presence of illegal herbal medicines\ncontaining harmful chemical ingredients.<\/p>\n
\u201cOn one hand, we want to encourage the growth of domestic\nfitofarmaka, but on the other, oversight of illegal herbal products must\nbe tightened to prevent the public from becoming victims of\nnon-compliant health products,\u201d she said.<\/p>\n
Furthermore, she called for cross-sector collaboration to strengthen\nthe fitofarmaka development ecosystem, from raw material supply to\nhealthcare application.<\/p>\n
\u201cWe need to build an ecosystem from upstream to downstream \u2013 starting\nwith raw material quality, production standardisation, clinical\nresearch, to healthcare professionals\u2019 literacy on evidence-based use of\nherbal medicines,\u201d she added.<\/p>\n
She noted that including fitofarmaka in BPJS Kesehatan coverage must\nalso consider the sustainability of JKN financing and patient medical\nneeds.<\/p>\n
\u201cThe primary goal of the healthcare system is patient safety and\nservice quality. Therefore, all policies must be evidence-based and\naccountably governed,\u201d she concluded.<\/p>", "url": "https:\/\/jawawa.id\/newsitem\/fitofarmaka-included-in-bpjs-kesehatan-coverage-commission-ix-stresses-scientific-evidence-1780156364", "image": "" }, "sponsor": "Okusi Associates", "sponsor_url": "https:\/\/okusiassociates.com" }